Using CAR T cells to target specific immune cells in Type 1 diabetes
Targeting cDC1 with CAR T cells to investigate their role and potential as a therapeutic target in Type 1 diabetes
This study is looking at how certain immune cells called cDC1 contribute to Type 1 diabetes and testing a new treatment using special CAR T cells to target and reduce these cells, which could help prevent or manage the disease in people.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10996718 on NIH RePORTER |
What this research studies
This research investigates the role of conventional type 1 dendritic cells (cDC1) in the development of Type 1 diabetes (T1D) and explores a novel therapy using CAR T cells to target these immune cells. The approach involves creating CAR T cells that specifically deplete cDC1, which are known to contribute to the autoimmune response that damages insulin-producing cells in the pancreas. By blocking the activity of these dendritic cells, the research aims to prevent the onset of T1D in a mouse model that closely resembles human disease. If successful, this could lead to new therapeutic strategies for managing or preventing T1D in patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for developing Type 1 diabetes, particularly children and adolescents with a family history of the disease.
Not a fit: Patients who already have established Type 1 diabetes or those with other autoimmune conditions unrelated to T1D may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic approach to prevent or delay the onset of Type 1 diabetes in at-risk individuals.
How similar studies have performed: Other research has shown promise in targeting immune cells for autoimmune diseases, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Abousaway, Omar — Washington University
- Study coordinator: Abousaway, Omar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.